Search results
Results from the WOW.Com Content Network
And since it split from Abbott in 2013, AbbVie has raised its payout by 288%. The ability to maintain a solid dividend program for years is an incredibly attractive quality to long-term investors.
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development , over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t ...
This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the ...
AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott Laboratories in 2013, the pharmaceutical titan has been a dividend ...
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...